Phosphodiesterase-4 inhibitor

Mar 26, 2020

Medimetriks Announces that Otsuka Achieved Positive Top-Line Phase 3 Results for MM36 (difamilast) in Japanese Adult and Pediatric Atopic Dermatitis Patients

Jun 18, 2019

Medimetriks Pharmaceuticals Focuses on Advancing MM36 (difamilast) Through Phase 3 Trials; Extinguishes Debt Owed to Knight Therapeutics

Apr 30, 2019

Psoriatic Arthritis Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Oct 31, 2018

Atopic Dermatitis Drugs Market Size Worth $6.41 Billion by 2022: Grand View Research, Inc.

Feb 12, 2018

Sun Pharma Announces Twelve Tildrakizumab Abstracts to be Presented at American Academy of Dermatology 2018 Annual Meeting

Feb 02, 2018

Growth of Sanofi-Regeneron's Dupixent in Atopic Dermatitis May Be Facing Its First Plateau, while Pfizer's Eucrisa Carves a Niche with Younger Patients

Nov 07, 2017

New Preclinical Research Suggests Utility of Tetra Discovery Partners' BPN14770 to Provide Therapeutic Benefit in Fragile X Syndrome

Sep 06, 2017

Medimetriks Announces Phase 2 Study Results Demonstrating Early Itch Relief for Topical PDE4 Inhibitor MM36 in Patients with Atopic Dermatitis